Deucrictibant efficacy and safety
9 evidence topics · 29 sources
Summary: RAPIDe-3 phase 3 design and analysis sets
- RAPIDe-3 compared oral deucrictibant immediate-release capsule 20 mg with placebo in a randomised, double-blind, two-period, two-sequence (2 × 2) crossover design. Participants were randomly allocated 1:1 to a deucrictibant-placebo or placebo-deucrictibant sequence to treat two qualifying attacks, stratified by age (≥12 to <18 years or ≥18 years) and by concomitant long-term prophylaxis use at screening. A washout of at least 72 h was required before the next attack was treated with study drug.
- Adolescents aged ≥12 to <18 years and adults aged ≥18 to ≤75 years with hereditary angioedema, including normal C1 inhibitor with a documented genetic variant, were eligible if they had at least two attacks in the 3 months before screening and experience effectively using conventional on-demand therapy; participants using long-term prophylaxis were also eligible.
- Qualifying attacks were non-laryngeal attacks with at least one AMRA symptom item score of 20 or more, or non-severe laryngeal attacks without breathing difficulties or stridor. Adults with severe laryngeal attacks and adolescents with laryngeal attacks of any severity were instructed to take conventional on-demand therapy instead of study drug.
- The sample size calculation assumed median times to onset of symptom relief of 2 h with deucrictibant and 5 h with placebo; 60 participants in the primary efficacy analysis set would provide at least 90% power, and approximately 120 participants were planned for enrollment.
- Between April 4, 2024, and Sept 1, 2025, 134 participants (ten [7%] adolescents and 124 [93%] adults) were enrolled and randomly allocated at 59 sites across 24 countries in the publication, and the registry record lists 76 locations. 113 participants treated 201 attacks, and the primary efficacy analysis set comprised 88 participants who treated one attack with each study drug (176 attacks). The sponsor ended the trial once the prespecified number of participants with paired treated attacks was reached, before all participants had treated two attacks.
- Of the 134 participants, 58 (43%) were male and the median age was 38.0 years (IQR 27.0 to 50.0); four (3%) had hereditary angioedema with normal C1 inhibitor. Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis.
- Primary analyses used the primary efficacy analysis set; sensitivity and subgroup analyses used all participants with at least one treated attack; safety analyses included all participants who received at least one dose, were based on actual treatment, and were descriptive. Use of rescue or selected prohibited medication was counted as treatment failure, and a gatekeeping procedure controlled the type 1 error rate at a two-sided alpha of 0.05 across the primary endpoint and the secondary endpoints in a fixed order.
Summary: RAPIDe-3 primary and key secondary endpoints
In the primary efficacy analysis set of 88 participants with paired attacks (post-treatment data for 83 deucrictibant-treated and 87 placebo-treated attacks for most endpoints), results for deucrictibant and placebo, respectively, were:
- Primary endpoint, time to onset of symptom relief (PGI-C rating of at least a little better for two consecutive timepoints within 12 h): median 1.28 h (95% CI 1.05 to 1.52) and more than 12 h (5.82 to >12); p<0.0001.
- Onset of symptom relief at 4 h: 69 (83%) of 83 and 24 (28%) of 87 attacks; p<0.0001.
- Time to substantial symptom relief (PGI-C): median 2.85 h (2.08 to 3.35) and more than 12 h (10.30 to >12).
- Time to reduction in attack severity (PGI-S): median 2.41 h (1.70 to 2.98) and more than 12 h (12.34 to >12).
- Time to complete symptom resolution (PGI-S rating of none within 48 h): median 11.95 h (8.61 to 21.79) and more than 48 h (>48 to >48).
- Time to end of progression (PGI-C): median 17.47 min (16.27 to 19.17) and 228.67 min (61.82 to 599.60).
- Complete symptom resolution with one dose at 24 h (PGI-S): 50 (60%) of 83 and 13 (15%) of 88 attacks.
- Endpoints assessed with AMRA: median 3.37 h and more than 12 h to substantial symptom relief, 6.94 h and more than 24 h to almost complete or complete symptom resolution, and 25.25 min and 272.09 min to end of progression.
- p<0.0001 for each secondary endpoint listed above. The primary endpoint and the secondary endpoints were reached within their prespecified timeframes by 82% to 93% of deucrictibant-treated attacks and 37% to 61% of placebo-treated attacks.
- Prespecified sensitivity analyses in the 113 participants with at least one treated attack, and supplementary analyses of the primary endpoint in the per-protocol set and with a treatment policy strategy, were reported as consistent with the primary analyses.
Summary: RAPIDe-3 second capsule and rescue medication use
- In the primary analysis of 88 paired attacks, 73 (83%) and 69 (78%) of 88 deucrictibant-treated attacks and 29 (33%) and 27 (31%) of 88 placebo-treated attacks were treated with a single capsule within 12 h and 24 h, respectively.
- A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively. A second capsule was permitted 4 h or later after the first, and for laryngeal attacks it was not permitted.
- Conventional on-demand therapy was used as rescue medication within 12 h for six (7%) of 88 deucrictibant-treated attacks and 32 (36%) of 88 placebo-treated attacks, and within 24 h for eight (9%) and 39 (44%), respectively (p<0.0001).
- Of the 77 deucrictibant-treated attacks that reached end of progression within 12 hours, 75 (97.4%) were treated with a single capsule, and more than 95% of deucrictibant-treated attacks maintained the predefined endpoints throughout their assessment periods.
Summary: RAPIDe-3 adolescents and subgroups
- Ten adolescents (7%) were enrolled, and 5 (5.7%) of the 88 participants in the primary efficacy analysis set were aged ≥12 to <18 years. Adolescents had a body weight requirement of ≥40 kg.
- Before randomisation, the ten adolescents each received one deucrictibant capsule in a non-attack state. Mean plasma levels reached the EC85 of 13.8 ng/mL within 15 min and were maintained to at least the last measured time point of 8 h. Three (30%) of the ten adolescents reported treatment-emergent adverse events (four events) after this dose, none related to study drug.
- In participants with at least one treated attack, outcomes were reported as consistent across subgroups defined by age, hereditary angioedema type, use of long-term prophylaxis, and attack location and severity.
- In the two participants with hereditary angioedema with normal C1 inhibitor, each with one deucrictibant-treated attack, time to onset of symptom relief was 1.53 h and 0.84 h; the authors stated that “the small dataset and absence of placebo control prevent further speculation on these findings”.
- Median time to onset of symptom relief with deucrictibant and placebo was 1.20 h and 6.55 h in the North America subgroup (38 participants) and 1.28 h and more than 12 h in the Europe and rest of world subgroup (96 participants).
Summary: RAPIDe-3 safety
- In the safety analysis set, 24 (24%) of 100 participants receiving deucrictibant and 17 (17%) of 101 receiving placebo reported treatment-emergent adverse events; within 3 days of treatment, the window the authors considered temporally clinically relevant, the figures were 15 (15%) and two (2%), and all events within 3 days were mild or moderate.
- Six treatment-related events in five (5%) deucrictibant-treated participants (one event each of dyspepsia, fatigue, lethargy, brain fog, headache, and somnolence) resolved within 24 h; one related event of pruritus occurred with placebo.
- One (1%) participant in each group had a serious adverse event: a laryngeal attack requiring hospital admission 132 days after deucrictibant, and a spontaneous miscarriage 45 days after placebo. None of the serious or severe events were considered related to study drug.
- No treatment-emergent adverse events led to treatment discontinuation or death, and none were associated with changes in clinical laboratory, vital sign, or electrocardiogram parameters. No difficulty swallowing the capsule was reported, including for laryngeal attacks, and no vomiting after study drug was reported in participants with abdominal symptoms.
Summary: RAPIDe-1 phase 2 dose-ranging results and safety
- RAPIDe-1 was a double-blind, randomised, placebo-controlled, crossover, dose-ranging, 2-part phase 2 trial in adults aged 18 to 75 years with hereditary angioedema type 1 or 2. Participants were randomly assigned 1:1:1 to deucrictibant 10 mg, 20 mg, or 30 mg and to one of three sequences treating three attacks (two with deucrictibant and one with placebo). Patients receiving long-term prophylaxis at screening were not eligible, and attacks involving the internal head or neck, including laryngeal attacks, or presenting with vomiting did not qualify.
- 74 participants were randomly assigned; the primary efficacy analysis included 147 attacks in 62 participants, of whom 42 (68%) were female and 60 (97%) were White.
- Primary endpoint, change in VAS-3 score from pre-treatment to 4 h: least squares mean difference versus placebo of −15.02 (95% CI −20.22 to −9.81) for 20 mg and −16.28 (−21.27 to −11.29) for 30 mg (p<0.0001 for both), and −16.75 (−21.52 to −11.97) for 10 mg, which was analysed descriptively without multiplicity control. All hypotheses in the 20 mg and 30 mg testing branches were rejected at the allocated α of 0.025.
- Median time to onset of symptom relief (≥30% reduction in VAS-3) was 2.1 h, 2.7 h, and 2.5 h with 10 mg, 20 mg, and 30 mg, and 8.0 h with placebo.
- Almost complete or complete symptom resolution within 24 h without rescue medication occurred in 71% (20 of 28) of attacks with 20 mg, 74% (23 of 31) with 30 mg, and 16% (eight of 51) with placebo. Rescue medication was used within 24 h for 9 (24%), 3 (11%), and 4 (13%) attacks with 10 mg, 20 mg, and 30 mg and 37 (73%) with placebo; median time to first rescue medication use was 6.0 h after placebo and non-evaluable after deucrictibant.
- In a post-hoc analysis of the same 147 attacks, median time to end of progression was 25 to 26 minutes with deucrictibant and 20 hours with placebo.
- Safety: in Part 1, eight (11%) of 72 participants in the safety analysis set reported treatment-emergent adverse events within 5 days, two of them mild treatment-related events (nausea and headache). In Part 2 (156 attacks), three moderate treatment-related events (nausea, vomiting, and fatigue) occurred in one participant about 20 h after a 30 mg dose, and one treatment-related blister occurred after placebo. No severe, serious, or discontinuation-related treatment-emergent adverse events were reported.
Summary: RAPIDe-2 long-term open-label extension results and safety
- RAPIDe-2 is a single-group phase 2/3 extension with no masking in its registry record. In Part A, adults who completed RAPIDe-1 remained blinded to their dose (10 mg, 20 mg, or 30 mg), treated every attack with active drug, could treat upper airway attacks including laryngeal attacks, and could not use long-term prophylaxis. Part B is open-label and includes participants aged 12 years and older rolling over from RAPIDe-3, and the registry admits participants on a stable long-term prophylaxis regimen. The primary endpoint is safety, analysed descriptively.
- Part A results, reported for the combined dose group, included 465 attacks treated by 19 participants. Median times were 1.1 h (95% CI 1.0 to 1.1) to onset of symptom relief, 2.5 h to substantial symptom relief, 2.8 h to reduction in attack severity, and 10.6 h to complete attack resolution.
- Onset of symptom relief by 12 hours was reached in 97.8% (447/457) of attacks and complete symptom resolution at 24 hours in 86.9% (390/449). A single dose was used for 86.2% (394/457) of attacks with post-treatment PGI-C data in one report and for 84.9% (395/465) of all treated attacks in another. Eight attacks used rescue medication within 24 hours.
- Among attacks that reached each milestone with a single dose, 98.3% (344/350) maintained onset of symptom relief and 99.2% (382/385) maintained complete attack resolution without symptom reoccurrence.
- Upper airway attacks: 14 upper airway attacks, including laryngeal attacks, were treated by seven participants, and difficulty swallowing or voice change was reported before treatment in six attacks. Median time to onset of symptom relief was 1.4 h (0.8 to 3.0) and to complete attack resolution 8.9 h (3.9 to 36.3), compared with 1.1 h and 10.6 h for all 451 non-upper airway attacks. One participant used rescue medication for one upper airway attack.
- Safety in Part A: 12 (2.6%) attacks had a treatment-emergent adverse event, with no treatment-related events. One serious event (tooth caries) was unrelated to treatment, and no events led to discontinuation, withdrawal, or death. In the ongoing Part B, 1 (0.9%) of 110 participants had a treatment-related tachycardia event and none had treatment-related vascular disorder events.
Summary: phase 1 pharmacology and integrated safety
- In PHA121-C001, 52 healthy participants received single ascending oral doses of an oral solution up to 22 mg and 16 received placebo. 17 adverse events were reported by 12 of 52 participants on study drug and 7 by 5 of 16 on placebo; none were serious or severe, and treatment-related events in three participants receiving 12 or 22 mg were mild gastrointestinal events. Across two single ascending dose studies (1 to 50 mg), adverse events occurred in 25% of participants on deucrictibant and 25% on placebo, with no dose-related increase.
- Peak plasma levels were reached within 30 to 60 minutes under fasted conditions, exposure was dose proportional, and mean half-life ranged from 3.5 to 5.6 h between doses. In a bradykinin challenge in 16 healthy volunteers, the average composite EC50 and EC85 were 2.4 and 13.8 ng/mL, and doses of 12 and 22 mg provided bradykinin antagonism for longer than a 30 mg subcutaneous icatibant injection.
- After a single 20 mg immediate-release capsule, mean plasma levels reached the EC85 within 15 to 30 min and were maintained for 8 h or longer; mean elimination half-life is approximately 5.1 h.
- As of June 10, 2026, an estimated 743 unique participants had been exposed to deucrictibant across 25 company-sponsored studies (339 healthy participants, 16 with hepatic impairment, 24 with renal impairment, and approximately 312 with hereditary angioedema).
- No treatment-related cardiac or vascular disorder adverse events occurred across the phase 1 single-dose studies, RAPIDe-1, the randomised part of CHAPTER-1 (twice-daily immediate-release capsules), RAPIDe-2 Part A, or RAPIDe-3. In phase 1 multiple-dose studies, 1 (0.4%) of 232 healthy participants had treatment-related orthostatic hypotension.
- A concentration-QTcF analysis of pooled phase 1 studies estimated a ΔΔQTcF of −2.55 ms (upper 90% CI +2.29 ms) at the highest estimated clinical exposure, below the 10 ms regulatory threshold, and the FDA accepted thorough QT study waiver requests for the immediate-release and extended-release formulations.
- In August 2022 the FDA placed a clinical hold on US trials based on repeat-dose rat findings; after review of an interim analysis of a 26-week rodent toxicology study, the hold on the on-demand application was lifted in June 2023.
- Pregnant and breastfeeding women were not eligible for RAPIDe-1 or RAPIDe-3, and both trials excluded participants with abnormal hepatic function and with abnormal renal function. Single-dose pharmacokinetic studies in hepatic impairment and in renal impairment are listed by the company.
Summary: differences between reporting documents
The documents report the following figures differently; each is given with its source.
- RAPIDe-3 median time to end of progression: 17.47 min in the Lancet publication and 17.48 minutes in the NDA acceptance release.
- RAPIDe-3 placebo median time to complete symptom resolution: more than 24 hours in the December 2025 topline release, and more than 48 h in the Lancet publication and the Form 20-F.
- RAPIDe-3 dates and sites: registry study start 2024-02-26 with 76 locations; screening from April 4, 2024, at 59 sites across 24 countries in the Lancet publication; trial initiation in March 2024 in the Form 20-F.
- RAPIDe-3 group sizes: the Lancet safety table counts 100 participants receiving deucrictibant and 101 receiving placebo, while its attack counts are 101 deucrictibant-treated and 100 placebo-treated attacks. The topline presentation states that one participant randomized to the deucrictibant-placebo sequence was incorrectly given placebo for the first attack.
- RAPIDe-1 sites: 38 in the Lancet Haematology publication, 36 locations in the registry, 33 sites (13 countries) in the topline release, and about 30 sites in a March 2023 presentation.
- RAPIDe-1 10 mg results: the publication reports no p value for 10 mg and analysed it descriptively, while the registry gives a nominal p value of <0.0001 for the primary endpoint and the topline release gives p values for 10 mg rescue medication use.
- RAPIDe-1 safety analysis set: 72 participants in Part 1 in the publication, and 156 attacks from 73 participants in a March 2023 presentation.
- RAPIDe-2 planned enrollment: 150 in ClinicalTrials.gov and 72 in the EU Clinical Trials Register. Study code: PHA022121-C303 in the registry and C201 in a Form 20-F heading.
- RAPIDe-2 single-dose proportion: 86.2% (394/457 attacks with post-treatment PGI-C data) and 84.9% (395/465 treated attacks).
- Half-life: 3.5 to 5.6 h after single ascending doses of oral solution, 4.8 to 7.3 h after multiple dosing, 5.10 h after a 2 x 20 mg immediate-release capsule dose, and approximately 5.1 h in the Lancet publication.
- Food effect at 22 mg: AUClast 49% higher with a high-calorie, high-fat breakfast in one report, and AUCinf 42% higher in another report and the registration statement, the 42% figure attributed to a result “mainly caused by one outlier”.
- Duration above the EC85: approximately 12 h after 12 and 22 mg oral solution and after a 2 x 10 mg immediate-release capsule dose; 8 h or longer after the immediate-release capsule in RAPIDe-1; approximately 8 hours at 10 or 20 mg and more than 10 hours at 30 mg in a RAPIDe-1 poster.
- CYP3A4 exclusion: moderate or potent inhibitors or inducers in RAPIDe-1, and strong inhibitors or inducers in RAPIDe-3 and the RAPIDe-2 registry record.